More than 2.3 million new cases of breast cancer are diagnosed each year. During surgery, it has become standard practice to remove the primary tumour as well as the so-called sentinel lymph nodes (SLN), the lymph nodes that have the highest probability of being invaded by cancer cells. Unfortunately, the current clinical standard to detect SLNs comes with many downsides such as radioactive exposure, blue skin discoloration, and so on. We developed a new medicinal product capable of detecting SLNs using imaging techniques that are faster, cheaper, more accurate and more readily available. In this IOF project our medicinal product will undergo an in-depth safety evaluation, manufacturing and regulatory requirements will be assessed, and a detailed business plans and roadmaps for the (pre)clinical evaluation will be developed.